Deutsche Bank Ag\ Aura Biosciences, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 28,134 shares of AURA stock, worth $257,144. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,134

Previous 18,662 50.76%

Holding current value

$257,144

Previous $141,000 77.3%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$6.9 - $10.36 $65,356 - $98,129	9,472 Added 50.76%	28,134 $250,000
Q2 2024 Aug 14, 2024	BUY	$6.81 - $7.89 $19,817 - $22,959	2,910 Added 18.47%	18,662 $141,000
Q1 2024 May 15, 2024	BUY	$7.09 - $9.24 $33,514 - $43,677	4,727 Added 42.88%	15,752 $123,000
Q4 2023 Feb 14, 2024	SELL	$7.02 - $11.98 $3,067 - $5,235	-437 Reduced 3.81%	11,025 $97,000
Q3 2023 Nov 09, 2023	BUY	$8.97 - $12.38 $21,402 - $29,538	2,386 Added 26.29%	11,462 $102,000
Q2 2023 Aug 14, 2023	SELL	$8.51 - $13.33 $53,493 - $83,792	-6,286 Reduced 40.92%	9,076 $112,000
Q1 2023 May 15, 2023	BUY	$8.88 - $12.11 $63,962 - $87,228	7,203 Added 88.28%	15,362 $142,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $1,222 - $1,809	124 Added 1.54%	8,159 $85,000
Q3 2022 Nov 14, 2022	SELL	$13.1 - $20.34 $16,060 - $24,936	-1,226 Reduced 13.24%	8,035 $146,000
Q2 2022 Aug 11, 2022	BUY	$12.37 - $21.86 $78,067 - $137,958	6,311 Added 213.93%	9,261 $131,000
Q1 2022 May 13, 2022	SELL	$15.94 - $23.34 $5,738 - $8,402	-360 Reduced 10.88%	2,950 $65,000
Q4 2021 Feb 11, 2022	BUY	$14.76 - $24.89 $48,855 - $82,385	3,310 New	3,310 $56,000

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $268M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account